This company has been acquired
La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
LogicBio Therapeutics Gestion
Gestion contrôle des critères 1/4
Informations clés
Fred Chereau
Directeur général
US$2.2m
Rémunération totale
| Pourcentage du salaire du PDG | 24.3% |
| Durée du mandat du directeur général | 6.6yrs |
| Propriété du PDG | 0.8% |
| Durée moyenne d'occupation des postes de direction | 1.8yrs |
| Durée moyenne du mandat des membres du conseil d'administration | 3.4yrs |
Mises à jour récentes de la gestion
Recent updates
LogicBio jumps 648% on buyout deal with AstraZeneca unit Alexion
Oct 03Bullish: Analysts Just Made A Notable Upgrade To Their LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Forecasts
Aug 20
LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Just Reported Second-Quarter Earnings And Analysts Are Lifting Their Estimates
Aug 18LogicBio GAAP EPS of -$0.15, revenue of $3.2M
Aug 15Is LogicBio Therapeutics (NASDAQ:LOGC) Weighed On By Its Debt Load?
Jan 11Does LogicBio Therapeutics (NASDAQ:LOGC) Have A Healthy Balance Sheet?
Aug 18LogicBio EPS misses by $0.06, beats on revenue
May 10LogicBio announces agreements with CANbridge Pharma and Daiichi Sankyo
Apr 27Is LogicBio Therapeutics (NASDAQ:LOGC) Using Debt Sensibly?
Apr 12Is LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Popular Amongst Insiders?
Mar 08The LogicBio Therapeutics (NASDAQ:LOGC) Share Price Has Gained 12% And Shareholders Are Hoping For More
Jan 15LogicBio extends collaboration with Children's Medical Research Institute
Jan 07LogicBio Therapeutics names new CFO
Dec 22Looking In On LogicBio
Nov 17LogicBio reports Q3 results
Nov 09Analyse de la rémunération des PDG
| Date | Rémunération totale | Salaire | Bénéfices de l'entreprise |
|---|---|---|---|
| Sep 30 2022 | n/a | n/a | -US$27m |
| Jun 30 2022 | n/a | n/a | -US$31m |
| Mar 31 2022 | n/a | n/a | -US$36m |
| Dec 31 2021 | US$2m | US$543k | -US$40m |
| Sep 30 2021 | n/a | n/a | -US$38m |
| Jun 30 2021 | n/a | n/a | -US$36m |
| Mar 31 2021 | n/a | n/a | -US$33m |
| Dec 31 2020 | US$2m | US$479k | -US$33m |
| Sep 30 2020 | n/a | n/a | -US$37m |
| Jun 30 2020 | n/a | n/a | -US$40m |
| Mar 31 2020 | n/a | n/a | -US$42m |
| Dec 31 2019 | US$633k | US$510k | -US$40m |
| Sep 30 2019 | n/a | n/a | -US$32m |
| Jun 30 2019 | n/a | n/a | -US$29m |
| Mar 31 2019 | n/a | n/a | -US$23m |
| Dec 31 2018 | US$2m | US$411k | -US$18m |
| Sep 30 2018 | n/a | n/a | -US$18m |
| Jun 30 2018 | n/a | n/a | -US$11m |
| Mar 31 2018 | n/a | n/a | -US$9m |
| Dec 31 2017 | US$779k | US$385k | -US$8m |
Rémunération vs marché: Fred's total compensation ($USD2.23M) is above average for companies of similar size in the US market ($USD750.11K).
Rémunération et revenus: Fred's compensation has increased whilst the company is unprofitable.
PDG
Fred Chereau (55 yo)
6.6yrs
Titularisation
US$2,228,208
Compensation
Mr. Frederic Chereau, M.B.A., also known as Fred, is the Chairman of the Board of Coave Therapeutics since October 2022 and has been its Independent Non-Executive Director since October 2021. He has execut...
Équipe de direction
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| President | 6.6yrs | US$2.23m | 0.77% $ 525.4k | |
| Co-Founder | no data | US$156.64k | 2.38% $ 1.6m | |
| Chief Medical Officer | 2.4yrs | US$1.54m | 0.010% $ 6.9k | |
| Co-Founder & Member of Scientific Advisory Board | no data | pas de données | pas de données | |
| Co-Founder | 8.3yrs | pas de données | pas de données | |
| Interim CFO | less than a year | pas de données | pas de données | |
| Global VP & Head of Technology Development | 3.6yrs | pas de données | pas de données | |
| Chief Scientific Officer | 2yrs | US$1.34m | pas de données | |
| General Counsel & Corporate Secretary | 1.5yrs | pas de données | pas de données | |
| VP & Head of Human Resources | 1.2yrs | pas de données | pas de données | |
| Senior Vice President of Strategy & Portfolio Management | 1.4yrs | pas de données | pas de données | |
| Chief Business Officer | 1.3yrs | pas de données | pas de données |
1.8yrs
Durée moyenne de l'emploi
55yo
Âge moyen
Gestion expérimentée: LOGC's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Membres du conseil d'administration
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| President | no data | US$2.23m | 0.77% $ 525.4k | |
| Co-Founder | 6.8yrs | US$156.64k | 2.38% $ 1.6m | |
| Co-Founder & Member of Scientific Advisory Board | no data | pas de données | pas de données | |
| Independent Director | 4.2yrs | US$87.39k | 0.0095% $ 6.5k | |
| Independent Chairman of the Board | 4.1yrs | US$113.64k | 0.012% $ 8.1k | |
| Independent Director | 2.7yrs | US$82.02k | 0.0089% $ 6.0k | |
| Member of Scientific Advisory Board | no data | pas de données | pas de données | |
| Independent Director | 6.8yrs | US$81.14k | 0.068% $ 46.2k | |
| Independent Director | 1.9yrs | US$76.77k | 0% $ 0 | |
| Independent Director | 1.9yrs | US$79.64k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | pas de données | pas de données | |
| Independent Director | less than a year | US$40.31k | pas de données |
3.4yrs
Durée moyenne de l'emploi
58yo
Âge moyen
Conseil d'administration expérimenté: LOGC's board of directors are considered experienced (3.4 years average tenure).